McKesson (MCK) Stock Forecast & Price Target

Q: What analysts cover McKesson?

McKesson has been rated by research analysts at Barclays , Citigroup , Evercore , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , TD Cowen , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$874.02 -5.55 (-0.63%)

Closing price 03:59 PM Eastern

Extended Trading

$874.15 +0.13 (+0.01%)

As of 07:07 PM Eastern

Compare

McKesson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for MCK.

Consensus Price Target

$973.44
11.37% Upside

According to the 18 analysts' twelve-month price targets for McKesson, the average price target is $973.44. The highest price target for MCK is $1,085.00, while the lowest price target for MCK is $845.00. The average price target represents a forecasted upside of 11.37% from the current price of $874.02.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MCK Analyst Ratings Over Time

Type	Current Forecast 9/18/25 to 9/18/26	1 Month Ago 8/19/25 to 8/19/26	3 Months Ago 6/20/25 to 6/20/26	1 Year Ago 9/18/24 to 9/18/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$973.44	$968.75	$960.53	$725.10
Forecasted Upside	11.37% Upside	13.50% Upside	28.03% Upside	5.03% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

McKesson Stock vs. The Competition

Type	McKesson	Healthcare Companies	Broader Market
Consensus Rating Score	2.78	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	11.37% Upside	754.94% Upside	18.42% Upside
News Sentiment Rating	Positive News See Recent MCK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/14/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Reiterated Rating	Sector Perform	$845.00	-5.64%
9/4/2026	Weiss Ratings 5 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
8/19/2026	Barclays 3 of 5 stars	Glen Santangelo Not Rated	Boost Target	Overweight	$925.00 ➝ $1,000.00	+14.98%
8/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$812.00 ➝ $933.00	+6.26%
8/7/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$1,015.00	+20.43%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$989.00 ➝ $1,006.00	+15.47%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,050.00 ➝ $1,080.00	+23.97%
7/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$945.00 ➝ $1,000.00	+21.26%
Get the Latest News and Ratings for MCK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.
5/8/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$875.00	+15.73%
5/8/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$1,107.00 ➝ $1,015.00	+37.07%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
4/6/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$1,040.00 ➝ $1,000.00	+16.29%
3/5/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$970.00	+4.12%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,085.00	+16.60%
2/5/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$880.00 ➝ $885.00	+7.98%
11/25/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/13/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$820.00 ➝ $900.00	+17.07%
4/4/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Sundaram Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:59 PM ET.

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 13, 2026. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

Here are some ways that investors could benefit from investing in McKesson Co.:

McKesson Co. recently reported strong financial performance, beating analyst expectations with earnings per share of $9.93 in the latest quarter, which exceeded the consensus estimate of $9.56, while also generating revenue of $105.38 billion that surpassed the projected $103.88 billion, demonstrating robust operational execution and demand for its healthcare distribution services.
The company has received a consensus rating of Moderate Buy from eighteen research firms, with an average twelve-month price target of $973.44, which represents significant upside potential from the current stock price of $880.52, indicating that analysts believe the stock is undervalued relative to its future earnings potential.
McKesson Co. recently increased its quarterly dividend to $0.94 per share, up from the previous $0.82, signaling management confidence in the company's cash flow generation and providing a growing income stream for investors, with an annualized dividend yield of approximately 0.43%.
Institutional investors have shown strong confidence in the company, with major funds such as BlackRock Inc. and Norges Bank establishing new positions in the recent quarters, while the California State Teachers Retirement System significantly increased its holdings, suggesting that large-scale investors view McKesson Co. as a stable and attractive long-term investment.
The stock exhibits a low beta of 0.30, indicating that it is less volatile than the overall market, which can provide a defensive characteristic for portfolios seeking stability, especially given the company's essential role in the healthcare supply chain and its consistent revenue growth of 7.7% year-over-year.

McKesson
Bear Case

Investors should be bearish about investing in McKesson Co. for these reasons:

Recent news reports indicate that McKesson Co. is facing legal challenges and security concerns, including lawsuits over a voice-phishing attack and exposure of data by security researchers, which could lead to increased compliance costs, reputational damage, and potential financial liabilities that may impact future earnings.
Insider selling has been notable, with the CEO Brian Tyler selling 8,463 shares in July 2026 and other executives such as the Chief Accounting Officer and EVPs also reducing their holdings in recent months, which may signal a lack of confidence from company leadership in the current stock valuation or future growth prospects.
The company reported a negative return on equity of 253.21% in the latest quarter, which, while potentially influenced by accounting adjustments or one-time charges, raises concerns about the efficiency of the company's use of shareholder capital and its ability to generate profits relative to its equity base.
Short interest in the stock has fluctuated, with a recent increase in shares shorted to 2.83 million as of August 2026, indicating that some investors are betting against the stock's price, which could create downward pressure on the share price if the short position is not covered quickly.
Despite the strong earnings, the stock price has experienced volatility, with a recent drop of 1.21% in a single trading session, and the current price of $880.52 is below the 52-week high of $999.00, suggesting that the market may be pricing in risks related to the healthcare sector or company-specific issues that have not yet been fully resolved.

MCK Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $973.44, with a high forecast of $1,085.00 and a low forecast of $845.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 11.37% based on their 12-month stock forecasts.

Over the previous 90 days, McKesson's stock had 1 upgrade and 1 downgrade by analysts.

McKesson has been rated by research analysts at Barclays, Citigroup, Evercore, Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, TD Cowen, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "healthcare" companies. The consensus rating for McKesson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MCK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With McKesson Recommendations

MarketBeat monitors more than a dozen sources for McKesson analyst ratings, with the most recent rating issued on 9/14/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

McKesson (MCK) Stock Forecast & Price Target